In a study from Baylor College of Medicine, 26 healthy volunteers were randomly assigned to take Fosamax
, naproxen, or both drugs together for 10 days, and then were evaluated by endoscopy for evidence of gastric ulcers.
After 2 years, those treated with Fosamax
had mean increases in bone mineral density (BMD) of the lumbar spine (7%), the femoral neck (2.
Bisphosphonates such as Fosamax
and Boniva are intended to slow bone loss associated with osteoporosis.
Unfortunately, the plaintiff had multiple medical conditions that cause people to develop the jaw and dental problems she claims she has, regardless of whether they were taking FOSAMAX
, said Christy Jones of Butler, Snow, O'Mara, Stevens & Cannada PLLC, outside counsel for Merck.
is part of the bisphosphonate family of osteoporosis drugs that include Procter & Gamble Co.
And dental treatment involving the jawbone, such as extractions, dental implants, periodontal surgery, root canals, and even simple fillings can trigger this condition in some women taking Fosamax
Unfortunately, the plaintiff had medical problems that cause people to develop the jaw and dental problems that the plaintiff has, regardless of whether they were taking FOSAMAX
Atelvia is in the same class of drugs--bisphosphonates--as the Fosamax
you are currently taking, along with Boniva and Reclast.
The PTH 1-84 (an investigational drug with a trade name of Preos) was stopped after 1 year, and 119 women who had been receiving Preos monotherapy were randomized to take either Fosamax
or placebo in the study's second year.
NEW ORLEANS -- Once-weekly Fosamax
produced a twofold greater increase in bone mineral density than daily Evista after 1 year of treatment in a head-to-head trial sponsored by Merck, which markets alendronate as Fosamax
If successful our challenge of the patents protecting the Fosamax
([R]) and FOSAMAX
PLUS D([R] )(alendronate sodium and cholecalciferol)
Millions of women take oral bisphosphonates such as Fosamax
, Actonel and Boniva in order to maintain or increase bone density and strength.
Merck, the maker of osteoporosis medicine Fosamax
and Singulair for asthma and allergies, reported net income of $473.
Greenspan, who is on the speaker's bureau for Merck, which markets Fosamax